Page 273 - Programme book for The International Liver Congress 2015, EASL ILC 2015
P. 273
YI P0879 EXAMINING THE CLINICAL COURSE OF GENOTYPE ePOSTERS
YI P0880 1 CHRONIC HEPATITIC C PATIENTS TREATED WITH
YI P0881 THE COSMOS REGIMEN: INCLUDING PATIENTS WITH
ADVANCED LIVER DISEASE, AND EAST ASIAN ANCESTRY
YI P0882 Marina Roytman, Resham Ramkissoon*, Leena Hong, Ruby Trujillo,
YI P0883 Leslie Huddleston, Peter Poerzgen, Todd Seto, Naoky Tsai,
The United States
PHARMACOGENOMIC STUDY TO PREDICT RIBAVIRIN AND
PROTEASE-INHIBITOR-RELATED ANEMIA IN HEPATITIS C
Javier Ampuero*, Lourdes Rojas, Jose Antonio Del Campo,
Jose Luis Calleja, Javier Crespo, Xavier Forns, Raúl Andrade, María Buti,
Inmaculada Fernández, Raquel Millán, Manuel Romero-Gómez, Spain
REAL WORLD EFFECTIVENESS AND COST OF
SIMEPREVIR- AND/OR SOFOSBUVIR-BASED HCV
TREATMENTS: $175,000 PER SVR12
Kian Bichoupan*, Neeta Tandon, David Del Bello, Neal Patel,
Rachana Yalamanchili, Sweta Chekuri, Alyson Harty, Sanders Chang,
Lawrence Ku, Michel Ng, David B. Motamed, Keith M. Sigel,
Donald Gardenier, Alicia Stivala, Viktoriya Khaitova, Meena B. Bansal,
Priya Grewal, Ritu Agarwal, Charissa Y. Chang, Jen Leong, Gene Y. Im,
Lawrence U. Liu, Joseph A. Odin, Nancy Bach, Scott L. Friedman,
Thomas D. Schiano, Ponni Perumalswami, Douglas T. Dieterich,
Andrea D. Branch, The United States
PILOT STUDY OF EZETIMIBE FOR CHRONIC HEPATITIS
C INFECTION: EFFECT OF TREATMENT IN PLASMA, BILE
AND STOOL VIRAL LOAD IN HUMANS
Hugo Monrroy*, Jennifer Angulo, Karla Pino, Juan Francisco Miquel,
Carlos Benitez, Marco Arrese, Francisco Barrera, Blanca Norero,
Rodrigo Wolff, Pilar Labbe, Marcelo Lopez-Lastra, Alejandro Soza, Chile
TREATMENT FOR HEPATITIS C VIRUS INFECTION
AMONG PEOPLE WHO INJECT DRUGS IN THE OPIOID
SUBSTITUTION SETTING: THE ETHOS STUDY
Maryam Alavi*, Jason Grebely, Michelle Micallef, Adrian Dunlop,
Annie Balcomb, Carolyn Day, Carla Treloar, Nicky Bath, Paul Haber,
Gregory Dore, Australia
Vienna, Austria • April 22–26, 2015 273
YI P0880 1 CHRONIC HEPATITIC C PATIENTS TREATED WITH
YI P0881 THE COSMOS REGIMEN: INCLUDING PATIENTS WITH
ADVANCED LIVER DISEASE, AND EAST ASIAN ANCESTRY
YI P0882 Marina Roytman, Resham Ramkissoon*, Leena Hong, Ruby Trujillo,
YI P0883 Leslie Huddleston, Peter Poerzgen, Todd Seto, Naoky Tsai,
The United States
PHARMACOGENOMIC STUDY TO PREDICT RIBAVIRIN AND
PROTEASE-INHIBITOR-RELATED ANEMIA IN HEPATITIS C
Javier Ampuero*, Lourdes Rojas, Jose Antonio Del Campo,
Jose Luis Calleja, Javier Crespo, Xavier Forns, Raúl Andrade, María Buti,
Inmaculada Fernández, Raquel Millán, Manuel Romero-Gómez, Spain
REAL WORLD EFFECTIVENESS AND COST OF
SIMEPREVIR- AND/OR SOFOSBUVIR-BASED HCV
TREATMENTS: $175,000 PER SVR12
Kian Bichoupan*, Neeta Tandon, David Del Bello, Neal Patel,
Rachana Yalamanchili, Sweta Chekuri, Alyson Harty, Sanders Chang,
Lawrence Ku, Michel Ng, David B. Motamed, Keith M. Sigel,
Donald Gardenier, Alicia Stivala, Viktoriya Khaitova, Meena B. Bansal,
Priya Grewal, Ritu Agarwal, Charissa Y. Chang, Jen Leong, Gene Y. Im,
Lawrence U. Liu, Joseph A. Odin, Nancy Bach, Scott L. Friedman,
Thomas D. Schiano, Ponni Perumalswami, Douglas T. Dieterich,
Andrea D. Branch, The United States
PILOT STUDY OF EZETIMIBE FOR CHRONIC HEPATITIS
C INFECTION: EFFECT OF TREATMENT IN PLASMA, BILE
AND STOOL VIRAL LOAD IN HUMANS
Hugo Monrroy*, Jennifer Angulo, Karla Pino, Juan Francisco Miquel,
Carlos Benitez, Marco Arrese, Francisco Barrera, Blanca Norero,
Rodrigo Wolff, Pilar Labbe, Marcelo Lopez-Lastra, Alejandro Soza, Chile
TREATMENT FOR HEPATITIS C VIRUS INFECTION
AMONG PEOPLE WHO INJECT DRUGS IN THE OPIOID
SUBSTITUTION SETTING: THE ETHOS STUDY
Maryam Alavi*, Jason Grebely, Michelle Micallef, Adrian Dunlop,
Annie Balcomb, Carolyn Day, Carla Treloar, Nicky Bath, Paul Haber,
Gregory Dore, Australia
Vienna, Austria • April 22–26, 2015 273
